



## Index

*Note:* Page numbers of article titles are in **boldface** type.

### A

- Abacavir, adverse reactions to, in HIV infection, 203
- ABCDs, to diagnose melanoma, 644, 671
- Ablative lasers, for striae distensae, 74
- Acanthosis nigricans  
  cutaneous features of, 525  
  in diabetes mellitus, 485  
  with thyroid disease, 478
- Acne scars, carbon dioxide laser therapy for, 83–84
- Acquired ichthyosis, cutaneous features of, 525–526
- Acquired perforating dermatosis  
  in diabetes mellitus, 485–486  
  in dialysis patients, 517
- Acral-mucosal regions, melanoma of, 669–670, 673
- Acrodermatitis enteropathica, with gastrointestinal disease, 538
- Acropachy, thyroid, cutaneous features of, 476
- Actinic cheilitis, laser therapy for, 153–154
- Actinic dermatitis, with HIV infection, 203
- Actinic keratoses, laser therapy for, 154–155
- Activated charcoal, for pruritus, 462
- Acyclovir  
  for cytomegalovirus infections, 296  
  for herpes simplex virus, 194, 256–259  
  for herpes zoster virus, 275–276  
  for human herpesvirus 6, 303  
  for varicella, 273–274
- Adhesion molecule expression, in cutaneous lupus erythematosus, 375
- AIDS, Kaposi's sarcoma in, 308
- Alexandrite lasers  
  for leg telangiectasias, 27–28  
  in hair removal, 140, 563–564  
  in tattoo removal, 49  
  parameters for, 5–6
- Allergic reactions  
  to insulin, for diabetes mellitus, 489  
  to pigments, in tattoos, 170–171
- AlloDerm, for chronic wounds, 361
- Alopecia areata, with thyroid disease, 477
- Alpha hydroxy acids, in skin preparation, for laser resurfacing, 116
- Amelanotic melanoma, diagnosis of, 727–728
- Amprenavir, adverse reactions to, in HIV infection, 203
- Amputation, ray, for subungual melanoma, 690
- Amyloidosis  
  cutaneous and renal features of, 516, 527  
  with cardiac disease, 506
- Anemia, with thyroid disease, 477
- Anesthesia  
  in tattoo removal, by laser, 50  
  regional. *See* Regional anesthesia.
- Anesthetic agents, for pruritus, 467
- Angiokeratoma corporis diffusum, with cardiac disease, 508
- Angiomas  
  cherry, laser therapy for, 13–14  
  spider, laser therapy for, 12
- Angiotensin-converting enzyme level, in sarcoidosis, 441
- Animal-derived materials, for chronic wounds, 358–359
- Anthranilates, in sunscreens, to prevent melanoma, 602–603

**Antibiotics**

- for infectious mononucleosis, adverse reactions to, 284
- for measles, 214

Antibody tests, for herpes simplex virus, 255

Antihistamines, for pruritus, 468

**Antimalarials**

- for cutaneous lupus erythematosus, 379
- for dermatomyositis, 400

Antimetabolites, for human papillomavirus, 321

Antiphospholipid antibody syndrome, cutaneous and renal features of, 515

Antiretroviral therapy, for HIV infection, 194

$\alpha_1$ -Antitrypsin deficiency, panniculitis with, 431

**Antiviral therapy**

- for enterovirus infections, 221
- for herpes simplex virus, resistance to, 259

Apligraf, for chronic wounds, 362

Apogee System, in hair removal, 140

Argon lasers, continuous-wave. *See* Continuous-wave argon lasers.

Argon-pumped tunable dye lasers  
for facial telangiectasias, 1  
parameters for, 2

Arthralgias, with hepatitis C, 454

**Arthritis**

- parvovirus B19 infection and, 339
- with dermatomyositis, 397
- with pyoderma gangrenosum, 414

Aseptic meningitis, clinical features of, 219

Aspirin, for pruritus, 465

Ataxia-telangiectasia, cutaneous features of, 553-554

Atrophic scars, revision of, lasers in, 57, 60-62

Atypical measles, clinical features of, 210

Augmerosin, for melanoma, 711

Auricular melanoma, Mohs' micrographic surgery for, 706

Australia, melanoma in, 589, 591, 632, 636

Autoantibodies, in dermatomyositis, 397-398

Azelastin, for pruritus, 462

**B**

Bacillary angiomatosis, with HIV infection, 197

**Bacterial infections**

- and scleredema, 493
- avoidance of, in laser skin resurfacing, 118, 168
- in diabetes mellitus, 488
- varicella and, 269
- with HIV infection, 197-198

*Bartonella* infections, with HIV infection, 197

Basal cell nevus syndrome, cutaneous features of, 550-551

**Bazex's syndrome**

- cutaneous features of, 526
- with gastrointestinal disease, 543

Becker's nevus, laser therapy for, 42

Behçet's disease, with cardiac disease, 506

Benign dermal lesions, laser therapy for, 157-158

Benzophenones, in sunscreens, to prevent melanoma, 602

Bichloroacetic acid, for human papillomavirus, 320

Biochemotherapy, for melanoma, 710

Bioengineered human skin, for chronic wounds, 359-362

Biofeedback, in psychodermatology, 178

Biologic therapy, for pyoderma gangrenosum, 416

Biopsy, of subungual melanoma, 690

Birt-Hogg-Dubé syndrome, cutaneous and renal features of, 514

Bleaching agents, in skin preparation, for laser resurfacing, 116-117

Blood products, and hepatitis C, 237-238

**Blue nevi**

- diagnosis of, 729-730
- laser therapy for, 45

**Botulinum toxin, 749-761**

- adverse effects of, 758
- contraindications to, 758
- for brow lift, 754-755
- for facial rhytides, 751-752
- for glabellar furrows, 752-753
- for horizontal forehead lines, 754-754
- for hyperhidrosis, 757
- for mentalis folds, 657
- for mouth frowns, 657
- for nasolabial folds, 657

- for periocular crow's feet, 755-756
  - for perioral rhytides, 657
  - for platysmal rejuvenation, 756-757
  - mechanism of action of, 749-750
  - preparation of, 751
  - response to, 758
  - sources of, 749
  - with brow lift, 757
  - with chemical peels, 757
  - with fillers, 757-758
  - with laser skin surfacing, 757
- Bourneville's disease, cutaneous and renal features of, 513-514
- Bowel associated dermatosis-arthritis syndrome, cutaneous features of, 416-417, 537-538
- Bowen's disease, laser therapy for, 155
- Brain, magnetic resonance imaging of, for congenital melanocytic nevi, 614
- Brain tumors, and pruritus, 466
- Breslow thickness, to classify melanoma, 647-648
- Brow lift
  - botulinum toxin for, 754-755
  - botulinum toxin with, 757
- Bullae
  - in diabetes mellitus, 484-485
  - in dialysis patients, 517
  - with thyroid disease, 477-478
- Bullous pyoderma gangrenosum
  - cutaneous features of, 413-414
  - diagnosis of, 348
- Burns, débridement of, carbon dioxide lasers in, 159
- C**
- Café-au-lait macules
  - in neurofibromatosis, 548
  - laser therapy for, 41-42, 171-172
- Calcifications, metastatic, in dialysis patients, 517-518
- Calciophylaxis
  - in dialysis patients, 518
  - panniculitis with, 430
- Calreticulin, in cutaneous lupus erythematosus, 375
- Candidal infections
  - with diabetes mellitus, 488
  - with HIV infection, 199-200
  - with thyroid disease, 478
- Capsaicin, for pruritus, 462
- Carbon dioxide lasers
  - for epidermal and dermal lesions, 147-151, 153-159
  - for human papillomavirus, 320
  - for leg telangiectasias, 24
  - for pigmented lesions, 38
  - in scar revision, 60-62
  - in skin resurfacing. *See* Skin resurfacing.
  - in tattoo removal, 49-50
- Carcinoid syndrome
  - cutaneous features of, 524
  - with cardiac disease, 506
  - with gastrointestinal disease, 543
- Cardiac disease, **503-511**
  - clubbing in, 504
  - coronary artery disease, 504-505
    - earlobe creases in, 504
    - hyperlipoproteinemia/xanthomas in, 504
    - peripheral vascular disease in, 504-505
  - cyanosis in, 503
  - erythema in, 503-504
  - flushing in, 503
  - inherited diseases, 507-509
    - Carney complex/myxoma, 509
    - Ehler-Danlos syndrome, 507-508
    - Fabry's disease, 508
    - LEOPARD syndrome, 509
    - Marfan's syndrome, 507
    - Naxos disease, 509
    - Noonan's syndrome, 508
    - pseudoxanthoma elasticum, 508
    - Werner syndrome, 508-509
  - multisystem disease, 505-507
    - amyloidosis, 506
    - Behçet's disease, 506
    - carcinoid syndrome, 506
    - Degos' disease/malignant atrophic papulosis, 506
    - hemochromatosis, 506-507
    - infective endocarditis, 507
    - Kawasaki's disease, 507
    - relapsing polychondritis, 505-506
    - scleroderma, 505
    - systemic lupus erythematosus, 505
- Cardiac features, of sarcoidosis, 438
- Cardio-facio-cutaneous syndrome, versus Noonan's syndrome, 508
- Carbustine, for melanoma, 709
- Carney complex, with cardiac disease, 509

- Carotenemia, in diabetes mellitus, 487
- Cellular immune mechanisms, in cutaneous lupus erythematosus, 374-375
- Cervical cancer, risk of, human papillomavirus in, 319-320
- Cheilitis, actinic, laser therapy for, 153-154
- Chemical cytodestruction, of human papillomavirus, 320
- Chemical peels, botulinum toxin with, 757
- Chemotherapy  
for Kaposi's sarcoma, 310  
for melanoma, **709-712**  
    combination, 709-710  
    immunomodulators with, 710  
    in limb perfusion, 710  
    new agents in, 711  
    single agents in, 709  
in limb perfusion, for recurrent melanoma, 688-689
- Cherry angiomas, laser therapy for, 13-14
- Chickenpox. *See* Varicella-zoster virus infection.
- Chilblain cutaneous lupus erythematosus, diagnosis of, 377
- Chloroquine  
for cutaneous lupus erythematosus, 379  
for dermatomyositis, 400
- Cholestasis, and pruritus, 462-464
- Cholesterol embolization syndrome, cutaneous and renal features of, 515
- Cholestyramine, for pruritus, 463, 465
- Chronic wounds, **357-363**  
animal-derived materials for, 358-359  
bioengineered human skin for, 359-362  
growth factors for, 357-358
- Cidofovir  
for cytomegalovirus infections, 296  
for human papillomavirus, 321  
for management-resistant herpes simplex virus, 259
- Cimetidine, for pruritus, 464-465
- Cinnamates, in sunscreens, to prevent melanoma, 602
- Cisplatin A, for melanoma, 709
- Clonidine, preoperative, in laser therapy, 127
- Clubbing  
in cardiac disease, 504  
in paraneoplastic dermatoses, 530
- Coagulopathy, cutaneous features of, 529
- Coccidioidomycosis, with HIV infection, 200
- Codeine, for pruritus, 464
- Composite Cultured Skin, for chronic wounds, 362
- Compound melanocytic nevi, laser therapy for, 43
- Computer-aided diagnosis, of melanoma, **735-747**  
confocal laser microscopy in, 744-745  
dermoscopic images in, 737-738  
for mole monitoring, 737  
hand-held probes in, 739-740  
machine vision in, 738-744  
teledermatology in, 736-737
- Condoms, to prevent herpes simplex virus, 260
- Condyloma acuminatum. *See* Human papillomavirus.
- Confocal laser microscopy  
of amelanotic melanoma, 727-728  
of congenital melanocytic nevi, 613  
of melanoma, 744-745
- Congenital melanocytic nevi, **607-616**, 662-663, 674-675  
classification of, 607  
diagnosis of, 610  
etiology of, 607-608  
    sunburns in, 613-614  
magnetic resonance imaging of brain for, 614  
management of, 612-613  
neurologic examination for, 614  
psychological burden of, 608  
risk factors for, 608, 610-612
- Congenital rubella syndrome. *See* Rubella.
- Conjunctivitis, hemorrhagic, clinical features of, 219
- Connective tissue diseases, with thyroid disease, 478
- Contact dermatitis, avoidance of, in skin resurfacing, 117-118
- Continuous-wave argon lasers  
for facial telangiectasias, 10  
for hemangiomas, 6-7  
for leg telangiectasias, 21-22  
for pigmented lesions, 37-38  
parameters for, 1-2
- Continuous-wave carbon dioxide lasers, for pigmented lesions, 38
- Continuous-wave dye lasers, for leg telangiectasias, 21-22

- Continuous-wave green light lasers, for pigmented lesions, 38
- Continuous-wave Nd:YAG lasers, for leg telangiectasias, 22
- Contour Er:YAG lasers, in skin resurfacing, 88, 91
- Copper bromide lasers  
for spider angiomas, 12  
parameters for, 12
- Copper vapor lasers  
for facial telangiectasias, 11  
for rosacea-associated telangiectasias and erythema, 12  
for spider angiomas, 12  
parameters for, 2
- Coronary artery disease. *See* Cardiac disease.
- Cowden disease, with gastrointestinal disease, 541-542
- Cowpox, cutaneous features of, 345
- Crohn's disease, cutaneous features of, 533
- Cronkhite-Canada syndrome  
cutaneous features of, 530  
with gastrointestinal disease, 541
- Crow's feet, botulinum toxin for, 755-756
- Cryoglobulinemia  
cutaneous and renal features of, 516, 530  
with hepatitis C, 450-451
- Cryotherapy, for human papillomavirus, 320
- Cryptococcosis, with HIV infection, 200
- Curettage and electrodesiccation, **569-577**  
cosmetic results of, 573-574  
cure rates in, 571-572  
followed by excision, 572  
histologic subtypes and, 573  
historical aspects of, 569-570  
rationale for, 574-576  
recurrence after, 572-573  
techniques for, 570-571  
types of curettes in, 570
- Cushing's syndrome, cutaneous features of, 524
- Cutaneous field stimulation, for pruritus, 468
- Cutaneous lupus erythematosus, **373-385**, 514-515  
diagnosis of, 375-378  
management of, 378-380  
pathogenesis of, 373-375  
cellular immune mechanisms in, 374-375  
environment in, 374  
genetic associations in, 373-374  
humoral immune mechanisms in, 375
- Cutaneous lymphomas, Epstein-Barr virus infection and, 286-287
- Cutaneous mucinoses, diffuse. *See* Diffuse cutaneous mucinoses.
- Cutaneous nephrology, **513-521**  
amyloidosis, 516  
antiphospholipid antibody syndrome, 515  
Birt-Hogg-Dubé syndrome, 514  
cholesterol embolization syndrome, 515  
cryoglobulinemia, 516  
dialysis patients, 516-518  
acquired perforating dermatosis, 517  
bullous disorders, 517  
calciophylaxis, 518  
metastatic calcifications, 517-518  
porphyria cutanea tarda, 517  
pruritus, 516-517  
end-stage renal disease, 516  
Fabry's disease, 514  
Henoch-Schönlein purpura, 515  
hyperoxaluria, 515  
lupus erythematosus, 514-515  
nail-patella syndrome, 514  
neurofibromatosis, 513  
partial lipodystrophy, 514  
polyarteritis nodosa, 515  
pseudoxanthoma elasticum, 514  
renal malignancies, 519  
renal transplant patients, 518-519  
systemic sclerosis, 515  
tuberous sclerosis, 513-514  
Wegener's granulomatosis, 515-516
- Cutaneous T-cell lymphoma  
Epstein-Barr virus infection and, 286-287  
pruritus with, 465
- CVD regimen, of chemotherapy, for melanoma, 710
- Cyanosis, in cardiac disease, 503
- Cyclosporine, for pyoderma gangrenosum, 353
- Cyproheptadine, for pruritus, 464
- Cytokines, in pruritus, 460
- Cytomegalovirus infections, **291-299**  
cutaneous features of, 293  
diagnosis of, 293-295  
management of, 295-296  
natural history of, 292-293  
virus binding and entry in, 292

- virus structure in, 291
  - with HIV infection, 195
- Cytophagic histiocytic panniculitis, cutaneous features of, 425, 428
- D**
- Dacarbazine, for melanoma, 709
- Dapsone
- for cutaneous lupus erythematosus, 379-380
  - for dermatomyositis, 400-401
- Darier-Roussy sarcoid, panniculitis with, 430, 436
- Deep-shave excision, of dysplastic nevi, 624
- Degos' disease
- with cardiac disease, 506
  - with gastrointestinal disease, 544-545
- Delavirdine, adverse reactions to, in HIV infection, 203
- Demodicosis, with HIV infection, 201
- Derma-K hybrid lasers, in skin resurfacing, 88, 91
- Dermagraft, for chronic wounds, 361
- Dermal lesions. *See* Epidermal and dermal lesions.
- Dermal replacement, for chronic wounds, 361-362
- Dermatitis
- actinic, with HIV infection, 203
  - contact, avoidance of, in laser skin resurfacing, 117-118
  - seborrheic, with HIV infection, 202
- Dermatitis herpetiformis, with gastrointestinal disease, 538-539
- Dermatologic complications, of herpes zoster virus, 273
- Dermatomyositis, **387-408**, 527-528
- arthritis with, 397
  - classification of, 390-391
  - complications of, 398-400
    - dystrophic calcification, 399-400
    - internal malignancies, 398-399
  - cutaneous features of, 393-395
  - differential diagnosis of, 400
  - epidemiology of, 391-393
  - etiology and pathogenesis of, 402-403
  - historical aspects of, 387-388
  - laboratory features of, 397-397
  - management of, 400-401
  - nomenclature in, 388-390
  - parvovirus B19 infection and, 339
- prognosis for, 401
  - pulmonary disease with, 395-397
- Dermatophyte infections, with HIV infection, 199
- Dermatoses
- neutrophilic. *See* Neutrophilic dermatoses.
  - paraneoplastic. *See* Paraneoplastic dermatoses.
- Dermatosis papulosa nigra, laser therapy for, 40-41
- Dermopathy, in diabetes mellitus, 484
- Dermoscopy
- of amelanotic melanoma, 727
  - of congenital melanocytic nevi, 613
  - of melanoma, 622, **641-646**, 737-738
    - ABCDs in, 644
    - algorithm for, 644
    - checklist for, 645
    - historical aspects of, 641
    - Menzies method in, 644
    - terminology in, 641-642
    - to differentiate malignant from benign lesions, 642-644
    - to differentiate melanotic from nonmelanotic lesions, 642
- Desmoplastic melanoma
- diagnosis of, 728-729
  - pathology of, 673
- Diabetes mellitus, **483-492**
- acanthosis nigricans in, 485
  - acquired perforating dermatosis in, 485-486
  - bacterial infections in, 488
  - bullae in, 484-485
  - dermopathy in, 484
  - diabetic foot in, 488-489
  - fungal infections in, 488
  - granuloma annulare in, 484
  - gustatory sweating in, 489
  - insulin for, cutaneous reactions to, 489
  - lichen planus in, 486
  - necrobiosis lipoidica in, 483-484
  - oral hypoglycemic agents for, cutaneous reactions to, 489-490
  - pruritus in, 466
  - rubeosis faciei in, 487
  - scleredema in, 494
  - thick skin in, 486-487
  - xanthoma in, 487
  - yellow skin in, 487
- Diabetic hand syndrome, glycemic control and, 487
- Dialysis patients, cutaneous and renal findings in. *See* Cutaneous nephrology.

- Dibenzoylmethanes, in sunscreens, to prevent melanoma, 603
- Diffuse cutaneous mucinoses, **493-501**  
 myxedema of hypothyroidism, 477, 498-499  
 reticular erythematous mucinosis, 497-498  
 scleredema, 493-495  
 scleromyxedema, 495-497
- Diode lasers  
 for leg telangiectasias, 28-29  
 in hair removal, 140, 564-566  
 in skin resurfacing, 100, 106-108  
 parameters for, 3, 6
- Diode-pumped vanadate lasers, for pigmented lesions, complications of, 172
- DNA polymerase inhibitors, for cytomegalovirus infections, 295
- Docetaxel, for melanoma, 709
- Doxepin, for pruritus, 468
- Drug reactions  
 with HIV infection, 203  
 with human herpesvirus 6, 308
- Drug use, intravenous, and hepatitis C, 238
- Dysplastic nevi, **617-628**, 681  
 biology of, 619-620  
 clinical features of, 620  
 genetics of, 617-618  
 histology of, 620-621  
 management of, 621-624  
 follow-up in, 621-622  
 genetic counseling in, 623  
 sunscreens in, 623  
 removal of, 623-624  
 scoring system for, 620
- Dysport. *See* Botulinum toxin.
- Dystrophic calcification, dermatomyositis and, 399-400
- E**
- E2000 Laser, in hair removal, 139
- Earlobe creases, in cardiac disease, 504
- Eccrine hidradenitis, neutrophilic, cutaneous features of, 417
- Eczema, with HIV infection, 201-202
- Eczema herpeticum, herpes simplex virus and, 253
- Ehlers-Danlos syndrome  
 with cardiac disease, 507-508  
 with gastrointestinal disease, 545
- Encephalitis, measles and, 211
- End-stage renal disease, cutaneous and renal features of, 516
- Endocarditis, infective, with cardiac disease, 507
- Endocrine dysfunction  
 and pruritus, 465-466  
 in ataxia-telangiectasia, 554
- Endocrine features, of sarcoidosis, 438
- Endocrinopathies, with thyroid disease, 478
- Enterovirus infections, **217-223**  
 clinical features of, 218-220  
 diagnosis of, 220  
 epidemiology of, 217-218  
 management of, 220-221  
 pathogenesis of, 217
- Environmental factors  
 in cutaneous lupus erythematosus, 374  
 in sarcoidosis, 440
- Enzyme linked immunosorbent assay, for measles, 211
- Eosinophilia myalgia syndrome, cutaneous features of, 423-424
- Eosinophilic fasciitis, cutaneous features of, 422-423
- Eosinophilic folliculitis, with HIV infection, 202-203
- Ephelides, laser therapy for, 41
- Epidermal and dermal lesions, laser therapy for, 39-40, 44, **147-164**  
 actinic cheilitis, 153-154  
 actinic keratoses, 154-155  
 benign growths, 157-158  
 carbon dioxide lasers in, 147-151, 153-159  
 condyloma acuminatum, 154  
 Er:YAG lasers in, 148-149  
 excisional, 158-159  
 inflammatory conditions, 155  
 laser-tissue interactions in, 147-148  
 nevi. *See* Nevi.  
 pulsed dye lasers in, 151-152  
 rhinophyma, 155-157  
 safety of, 148-149  
 seborrheic keratoses, 40-41, 155  
 skin cancer, 155  
 skin resurfacing in, 149-150

- technique for, 149-150
  - verrucae, 150-152
  - wound care in, 150
- Epidermal nevus syndrome, cutaneous features of, 551-552
- Epidermodysplasia verruciformis, human papillomavirus and, 318-319
- Epilaser, in hair removal, 139
- EpiPulse Ruby lasers, in hair removal, 139
- Epithelioid cell melanoma, of trunk and proximal extremities, 672
- Epitouch lasers, in hair removal, 140
- Epothilone, for melanoma, 711
- Epstein-Barr virus infection, 283-289
  - and cutaneous lymphomas, 286-287
  - and infectious mononucleosis, 283-285
  - and oral hairy leukoplakia, 285-286
  - historical aspects of, 283
  - with HIV infection, 195
- Erbium glass lasers, in skin resurfacing, 104-105
- Erbium lasers, in tattoo removal, 49-50
- Eruptive xanthomas, in cardiac disease, 504
- Er:YAG lasers
  - for epidermal and dermal lesions, 148-149
  - in scar revision, 61-62
  - in skin resurfacing. *See* Skin resurfacing.
- Erythema
  - in cardiac disease, 503-504
  - laser skin resurfacing and, 93, 168
  - necrolytic migratory, cutaneous features of, 523-524
- Erythema gyratum repens, cutaneous features of, 526
- Erythema infectiosum, parvovirus B19 infection and, 334-335
- Erythema multiforme, herpes simplex virus and, 253
- Erythema nodosum
  - cutaneous features of, 421-422
  - in sarcoidosis, 437
  - infectious mononucleosis and, 284
- Erythroplasia of Queyrat, laser therapy for, 155
- Erythroderma, cutaneous features of, 529
- Erythropoietin, for pruritus, 462
- E-selectin, in dermatomyositis, 398
- Exanthema subitum, human herpesvirus 6 and, 303
- Extracorporeal plasmapheresis, for pruritus, 463
- Extremities, proximal, melanoma of, 664-666, 672-673
- Eyelids, photodamaged, laser therapy for, 91

## F

- Fabry's disease
  - cutaneous and renal features of, 514
  - with cardiac disease, 508
- Facial aesthetics, botulinum toxin in. *See* Botulinum toxin.
- Facial blocks, in laser therapy, 128-130
  - complications of, 130
  - inadequate, 132
- Facial melanoma, surgery for, 691-692
- Facial rhytides, botulinum toxin for, 751-752
- Facial telangiectasias, laser therapy for, 10-11
  - complications of, 173
- Famciclovir
  - for herpes simplex virus, 256-259
  - for herpes zoster virus, 275
- Familial atypical mole and melanoma syndrome, biology of, 619
- FAS, in cutaneous lupus erythematosus, 375
- Fibromyalgia, with dermatomyositis, 395
- Fibrosis, pulmonary, with dermatomyositis, 396
- Fifth disease, parvovirus B19 infection and, 334-335
- Flashlamp-pumped pulse dye lasers. *See* Pulsed dye lasers.
- 5-Fluorouracil, for human papillomavirus, 321
- Flushing, in cardiac disease, 503
- Folliculitis
  - eosinophilic, with HIV infection, 202-203
  - with HIV infection, 197
- Fomivirsen, for cytomegalovirus infections, 296
- Fong's syndrome, cutaneous and renal features of, 514
- Forehead lines, botulinum toxin for, 753-754
- Foscarnet
  - adverse reactions to, in HIV infection, 203



- for cytomegalovirus infections, 295-296
- for management-resistant herpes simplex virus, 259
- for management-resistant herpes zoster virus, 276

#### Fungal infections

- in diabetes mellitus, 488
- with HIV infection, 199-200

### G

G-319, for melanoma, 711

#### Ganciclovir

- for cytomegalovirus infections, 295
- for human herpesvirus 6, 303

Gardner's syndrome, with gastrointestinal disease, 541

#### Gastrointestinal disease, 533-546

- acrodermatitis enteropathica with, 538
- Bazex's syndrome with, 543
- bowel associated dermatosis-arthritis syndrome with, 537-538
- carcinoid syndrome with, 543
- Cowden disease with, 541-542
- Crohn's disease, 533
- Cronkhite-Canada syndrome with, 541
- cutaneous eruptions due to malabsorption with, 538
- Degos' disease with, 544-545
- dermatitis herpetiformis with, 538-539
- Ehlers-Danlos syndrome with, 545
- Gardner's syndrome with, 541
- glucagonoma with, 543
- hereditary hemorrhagic telangiectasia with, 544
- Howell-Evans syndrome with, 542
- Kaposi's sarcoma with, 544
- lichen planus with, 539
- Muir-Torre syndrome with, 542
- multiple endocrine neoplasia with, 542
- necrotizing angitis with, 544
- pancreatic panniculitis with, 539
- Peutz-Jeghers syndrome with, 542
- Plummer-Vinson syndrome with, 542-543
- porphyria cutanea tarda with, 539
- pseudoxanthoma elasticum with, 545
- pustular reactions in, 538
- pyoderma gangrenosum with, 533-536
- Sweet's syndrome with, 536-537
- ulcerative colitis, 533

Genital ulcers, infectious mononucleosis and, 284-285

Genital warts. *See* Human papillomavirus.

Gentlelase, in hair removal, 140

German measles. *See* Rubella.

Gingival telangiectasia, in dermatomyositis, 394

Glabellar furrows, botulinum toxin for, 752-753

"Gloves and socks" syndrome, parvovirus B19 infection and, 335-336

Glucagonoma, with gastrointestinal disease, 543

Glycolic acid, in skin preparation, for laser resurfacing, 116

Gorlin syndrome, cutaneous features of, 550-551

Granulocyte-macrophage colony stimulating factor, for chronic wounds, 358

Granuloma annulare, in diabetes mellitus, 484

Granulomas, pyogenic, laser therapy for, 12-13

#### Graves' disease

- and pruritus, 465
- cutaneous features of, 475-476

Growth factors, for chronic wounds, 357-358

Gustatory sweating, in diabetes mellitus, 489

### H

Hair changes, in hypothyroidism, 477

#### Hair removal

- lasers in, 135-146, 561-567
  - alexandrite lasers, 140, 563-564
  - complication of, 143, 171
  - diode lasers, 140, 564-566
  - intense pulsed nonlaser light source, 566
  - long-pulsed Nd:YAG lasers, 141
  - microwave delivery systems in, 142
  - Nd:YAG lasers, 566-567
  - patient expectations in, 144
  - postoperative care for, 143
  - preoperative preparation for, 142
  - pulsed, noncoherent broadband light sources, 141-142
  - Q-switched Nd:YAG lasers, 137, 141
  - results of, 144
  - ruby lasers, 139-140, 562-563
  - safety of, 143-144
  - Softlight System, 137-139
  - technique for, 142-143
  - technology in, 135-138
  - terminology in, 138-139
  - photodynamic therapy in, 138

Hand-foot-mouth syndrome, clinical features of, 219

- Head and neck, melanoma of, 666-669, 673
- Healthcare workers
- hepatitis B in, 234
  - hepatitis C in, 238
- Hemangiomas, laser therapy for, 6-8
- complications of, 173
- Hematologic complications, of varicella, 270
- Hematopoietic diseases, and pruritus, 464-465
- Hemochromatosis, with cardiac disease, 506-507
- Hemorrhagic conjunctivitis, clinical features of, 219
- Henoch-Schönlein purpura, cutaneous and renal features of, 515
- Hepatic complications, of varicella, 270
- Hepatic features, of sarcoidosis, 438
- Hepatitis, viral. *See* Viral hepatitis.
- Hepatitis B immunoglobulin, to prevent hepatitis B, 236-237
- Hepatitis C, **449-458**
- arthralgias in, 454
  - co-infections with, 455
  - cryoglobulinemia in, 450-451
  - cutaneous features of, 450-454
  - diagnosis of, 454
  - etiology of, 449-450
  - lichen planus in, 452
  - lymphoproliferative disorders in, 454
  - management of, 454-455
  - pathogenesis of, 450
  - polyarteritis nodosa in, 453
  - porphyria cutanea tarda in, 451-452
  - pruritus in, 452-453
  - pyoderma gangrenosum in, 453
  - Sjögren's syndrome in, 452
  - systemic lupus erythematosus in, 453
  - urticaria in, 452
  - vitiligo in, 453
- Hepatobiliary disease, and pruritus, 462-464
- Herpangina, clinical features of, 219
- Herpes genitalis. *See* Herpes simplex virus.
- Herpes labialis. *See* Herpes simplex virus.
- Herpes simplex virus, **249-266**. *See also* Herpesviruses.
- clinical features of, 251-254
  - herpes genitalis, 251-252
  - herpes labialis, 251
  - in immunocompromised patients, 253-254
  - in neonates, 253
  - diagnosis of, 254-255
  - in pregnancy, 255
  - epidemiology of, 249-250
  - herpes genitalis, 249
  - herpes labialis, 249
  - etiology of, 249-250
  - herpes genitalis, 249
  - herpes labialis, 249
  - management of, 256-259
  - herpes genitalis, 258
  - herpes labialis, 257-258
  - in immunocompromised patients, 259
  - in pregnancy, 258-259
  - resistance to, 259
  - pathogenesis of, 250-251
  - herpes genitalis, 250-251
  - herpes labialis, 251
  - pathology of, 256
  - prevention of, 259-261
  - transmission of, 249-250
  - herpes genitalis, 249-250
  - in laser skin resurfacing, 168
  - with HIV infection, 250
- Herpes zoster virus. *See* Varicella-zoster virus infection.
- Herpesviruses, **302-306, 307-314**. *See also* Herpes simplex virus.
- human herpesvirus 6, 301-303
  - biology of, 302
  - diagnosis of, 303
  - disease associations with, 303
  - epidemiology of, 302
  - management of, 303
  - human herpesvirus 7, 303-305
  - biology of, 304
  - diagnosis of, 305
  - disease associations with, 304-305
  - epidemiology of, 304
  - management of, 305
  - human herpesvirus 8, **307-314**
  - and Kaposi's sarcoma, 307-310
  - clinical variants of, 307-308
  - epidemiology of, 309-310
  - management of, 310
  - molecular biology of, 309
  - and multicentric Castleman's disease, 310-311
  - and primary effusion lymphoma, 311
  - with HIV infection, 194-196
- Herpetic whitlow, clinical features of, 253

- Hidradenitis, neutrophilic eccrine, cutaneous features of, 417
- Highly active antiretroviral therapy, for HIV infection, 194
- Histamine, in pruritus, 459
- Histoplasmosis, with HIV infection, 200
- HIV infection, cutaneous features of, **193-208**  
adverse drug reactions, 203  
bacillary angiomatosis, 197  
candidal infection, 199-200  
coccidioidomycosis, 200  
cryptococcosis, 200  
cytomegalovirus, 195  
demodicosis, 201  
dermatophyte infection, 199  
eosinophilic folliculitis, 202-203  
herpes simplex virus, 194  
herpes zoster virus, 271  
herpesviruses, 194, 250  
histoplasmosis, 200  
human papillomavirus, 196, 319  
Kaposi's sarcoma, 195-196  
molluscum contagiosum, 196-197, 344  
mycobacterial infection, 197-198  
oral hairy leukoplakia, 195  
photosensitivity disorders, 203-204  
primary HIV infection, 193-194  
psoriasis and Reiter's syndrome, 202  
scabies, 201  
seborrheic dermatitis, 202  
staphylococcal infection and folliculitis, 197  
syphilis, 198  
varicella, 269  
varicella-zoster virus, 194-195  
xerosis and eczema, 201-202
- HLA antigens, in vaccines, for melanoma, 718-719
- HMB-45, in Mohs' micrographic surgery, for melanoma, 705
- Hodgkin's disease, pruritus with, 465
- Holster sign, in dermatomyositis, 394
- Human papillomavirus, **315-331**  
and epidermodysplasia verruciformis, 318-319  
classification of, 317  
epidemiology of, 319-320  
genital mucosal features of, 319  
in immunocompromised patients, 319  
laser therapy for, 153  
management of, 3202-323  
nongenital cutaneous features of, 317-318  
pathogenesis of, 316-317  
prevention of, 323-324  
virus structure in, 315-316  
with HIV infection, 196
- Humoral immune mechanisms, in cutaneous lupus erythematosus, 375
- Hydroquinone, in skin preparation, for laser resurfacing, 116-117
- Hydroxychloroquine  
for cutaneous lupus erythematosus, 379  
for dermatomyositis, 400
- Hyperhidrosis, botulinum toxin for, 757
- Hyperlipoproteinemia, in cardiac disease, 504
- Hyperoxaluria, cutaneous and renal features of, 515
- Hyperpigmentation  
laser hair removal and, 143  
laser skin resurfacing and, 93, 166  
laser tattoo removal and, 48  
postinflammatory, laser therapy for, 42
- Hypertension, regional anesthesia and, 132-133
- Hyperthyroidism  
and pruritus, 465  
cutaneous features of, 474-475
- Hypertrichosis lanuginosa acquisita, cutaneous features of, 525
- Hypertrophic cutaneous lupus erythematosus, diagnosis of, 376-377
- Hypertrophic scars, revision of, lasers in, 56, 59-60
- Hypnosis, in psychodermatology, 178-179
- Hypoglycemic agents, for diabetes mellitus, cutaneous reactions to, 489-490
- Hypopigmentation  
laser hair removal and, 143  
laser skin resurfacing and, 93-94, 166, 168  
laser tattoo removal and, 48
- Hypothyroidism  
and pruritus, 465-466  
cutaneous features of, 476-477  
myxedema of, 477, 498-499
- I**
- Ichthyosis, acquired, cutaneous features of, 525-526
- Idiopathic inflammatory myopathies.  
*See* Dermatomyositis.

- Idiopathic lobular panniculitis, cutaneous features of, 425
- Imiquimod, for human papillomavirus, 322
- Immunocompromised patients
- cytomegalovirus infections in, 293
  - herpes simplex virus in, 250
    - clinical features of, 253-254
    - management of, 259
  - herpes zoster virus in, 271
  - human papillomavirus in, 319
  - measles in, 210
  - varicella in, 268-269
- Immunomodulators
- for melanoma, 710
  - for recurrent melanoma, 689-690
- Immunosuppressive therapy
- for cutaneous lupus erythematosus, 379
  - for pyoderma gangrenosum, 416
- Immunotherapy, with surgery, for melanoma, 686-687
- In situ hybridization technique, for cytomegalovirus infections, 294
- Incontinentia pigmenti, cutaneous features of, 554-555
- Indinavir, adverse reactions to, in HIV infection, 203
- Infections
- and sarcoidosis, 440
  - bacterial, avoidance of, in laser skin resurfacing, 118, 168
  - in diabetes mellitus, 488
  - panniculitis with, 430-431
- Infectious mononucleosis, Epstein-Barr virus infection and, 283-285
- Inflammatory bowel disease, cutaneous features of, 533
- Inflammatory disorders, laser therapy for, 155
- Inflammatory response, in melanoma, 652
- Infra-orbital nerve blocks, in laser therapy, 130
- Infrared lasers, for striae distensae, 69
- Insulin, for diabetes mellitus, cutaneous reactions to, 489
- Integra Dermal Regeneration Template, for chronic wounds, 361
- Intense pulsed light source
- for leg telangiectasias, 14, 31-33
  - in hair removal. *See* Hair removal.
  - in skin resurfacing, 101-102
  - parameters for, 5
- Interferons
- for hepatitis B, 237
  - for hepatitis C, 454
  - for human papillomavirus, 321-322
  - for lichen planus, 242
  - for melanoma, 710
    - with surgery, 686
  - for mixed cryoglobulinemia, 240
  - for porphyria cutanea tarda, 241
  - for pruritus, 465
- Interleukins, for melanoma, 710
- Interstitial pneumonitis, with dermatomyositis, 396-397
- Intratumoral therapy, for recurrent melanoma, 689-690
- Intravenous drug use, and hepatitis C, 238
- Intravenous immunoglobulin, for parvovirus B19 infection, 340
- Iron supplementation, for pruritus, 465
- 
- J**
- Jaw cysts, in basal cell nevus syndrome, 551
- Junctional melanocytic nevi, laser therapy for, 43
- 
- K**
- Kaposi's sarcoma
- human herpesvirus 8 and. *See* Herpesviruses.
  - with gastrointestinal disease, 544
  - with HIV infection, 195-196
- Kaposi's varicelliform eruption, herpes simplex virus and, 253
- Kawasaki's disease, with cardiac disease, 507
- Keloids, revision of, lasers in, 56-57, 59-60, 159
- Keratinocyte-derived growth factor, for chronic wounds, 358
- Keratosis
- actinic, laser therapy for, 154-155
  - seborrheic, laser therapy for, 40-41, 155
- Ketamine, intraoperative, in laser therapy, 128
- Ketorolac, postoperative, in laser therapy, 133
- KL-6, in dermatomyositis, 398

Krypton lasers  
for pigmented lesions, complications of, 172  
parameters for, 2

KTP lasers  
for leg telangiectasias, 24  
for rosacea-associated telangiectasias and  
erythema, 12  
in skin resurfacing, 102-103  
parameters for, 2-3

## L

Lactate dehydrogenase, in metastatic  
melanoma, 649

Lamivudine, for hepatitis B, 237

Laser therapy. *See also* Lasers.  
complications of, 165-176  
for cutaneous lupus erythematosus, 378-379  
for epidermal and dermal lesions. *See* Epidermal  
and dermal lesions.  
for human papillomavirus, 320  
for leg telangiectasias. *See* Leg telangiectasias.  
for pigmented lesions. *See* Pigmented lesions.  
for vascular lesions. *See* Vascular lesions.  
patient selection for, 165  
regional anesthesia in. *See* Regional anesthesia.

Lasers. *See also* Laser therapy.  
in hair removal. *See* Hair removal.  
in scar revision. *See* Scar revision.  
in skin resurfacing. *See* Skin resurfacing.  
in tattoo removal. *See* Tattoo removal.

Leg telangiectasias  
diagnosis of, 19-20  
laser therapy for, 14, 19-36  
carbon dioxide lasers in, 24  
complications of, 173-174  
continuous-wave argon and dye lasers in,  
21-22  
continuous-wave Nd:YAG lasers in, 22  
cooling in, 33-34  
diode lasers in, 28-29  
indications for, 34  
intense pulsed light source in, 14, 31-33  
KTP lasers in, 24  
long-pulsed alexandrite lasers in, 27-28  
long-pulsed dye lasers in, 14, 26-27  
long-pulsed Nd:YAG lasers in, 29-30  
parameters for, 21  
pulsed dye lasers in, 14, 24, 26  
ultra-long pulsed dye lasers in, 14

Lentiginos, laser therapy for, complications of, 172

Lentigo maligna  
histogenesis of, 659  
laser therapy for, 155  
Mohs' micrographic surgery for, 705  
radiation therapy for, 714

Lentigo simplex, laser therapy for, 40

LEOPARD syndrome, with cardiac disease, 509

Leukemia, panniculitis with, 430

Leukine, for chronic wounds, 358

Libman-Sachs endocarditis, in systemic lupus  
erythematosus, 505

Lichen myxedematosus, cutaneous features of,  
495-497

Lichen planus  
hepatitis C and, 241-242  
with diabetes mellitus, 486  
with gastrointestinal disease, 539  
with hepatitis C, 452

Limb perfusion  
for melanoma, 710  
for recurrent melanoma, 688-689

Lipoatrophy, in diabetes mellitus, insulin and, 489

Lipodermatosclerosis, cutaneous features of, 422

Lipodystrophy  
in dermatomyositis, 394  
partial, cutaneous and renal features of, 514

Lipohypertrophy, in diabetes mellitus, insulin  
and, 489

Lomustine, for melanoma, 709

Long-pulsed alexandrite lasers, for leg telangiectasias,  
27-28

Long-pulsed dye lasers  
for leg telangiectasias, 14, 26-27  
for pigmented lesions, 39  
parameters for, 4

Long-pulsed Er:YAG lasers, in scar revision,  
61-62

Long-pulsed KTP lasers, in skin resurfacing,  
102-103

Long-pulsed Nd:YAG lasers  
for leg telangiectasias, 29-30  
in hair removal, 141  
in skin resurfacing, 102-103

Loop electrosurgical excision, for human  
papillomavirus, 320

Lupus band test, for cutaneous lupus erythematosus, 376

**Lupus erythematosus**

- cutaneous. *See* Cutaneous lupus erythematosus.
- renal features of, 514-515
- systemic, with cardiac disease, 505
- versus reticular erythematous mucinosis, 497
- with hepatitis C, 453
- with panniculitis, 430

Lupus panniculitis, diagnosis of, 377

Lupus pernio, in sarcoidosis, 435-436

Lymph nodes, in melanoma, 684-686

Lymphangioma circumscriptum, laser therapy for, 157-158

**Lymphomas**

- cutaneous T-cell
  - Epstein-Barr virus infection and, 286-287
  - pruritus with, 465
  - panniculitis with, 430
  - primary effusion, human herpesvirus 8 and, 311

Lymphoproliferative disorders, with hepatitis C, 454

---

**M**

Macrometastases, from melanoma, 648

**Magnetic resonance imaging**

- of brain, for congenital melanocytic nevi, 614
- of dystrophic calcification, in dermatomyositis, 399-400

Magnetic resonance spectroscopy, of muscle abnormalities, in dermatomyositis, 394-395

Malabsorption, cutaneous eruptions due to, 538

**Malignancies**

- and pruritus, 466
- internal, dermatomyositis and, 398-399, 527
- renal, cutaneous and renal features of, 519
- with pyoderma gangrenosum, 414

Malignant atrophic papulosis, with cardiac disease, 506

Malignant pyoderma, cutaneous features of, 413

Malignant skin tumors, human papillomavirus and, 318

Marfan's syndrome, with cardiac disease, 507

Mastocytosis, pruritus with, 465

McCune-Albright syndrome, with thyroid disease, 478

**Measles, 209-215**

- clinical features of, 210
- complications of, 210-211
- diagnosis of, 211
- epidemiology of, 211-212
- immune response in, 209-210
- in immunocompromised patients, 210
- laboratory findings in, 211
- management of, 214
- mumps, rubella vaccine, complications of, 229
- pathogenesis of, 209-210
- prevention of, 212-214

Mechanic's hand lesion, in dermatomyositis, 393

Mel-5, in Mohs' micrographic surgery, for melanoma, 705

MelaFind probe, to diagnose melanoma, 739-740

Melan-A antigen, in Mohs' micrographic surgery, for melanoma, 705

Melanocytic nevi, congenital. *See* Congenital melanocytic nevi.

**Melanoma**

- biology of, 701
- biopsy of, 677-680, 682
  - decision making in, 677
  - excisional, 678-679
  - incisional, 679
  - saucerization in, 679
  - terminology in, 678
- chemotherapy for. *See* Chemotherapy.
- dermoscopy of. *See* Dermoscopy.
- diagnosis of, 622, 682
  - computer-aided. *See* Computer-aided diagnosis.
  - frozen sections in, 703
- epidemiology of, 681-682
- incidence of, 589-595
  - artifacts in, 593
  - body site and, 592-593
  - geographic location in, 589
  - in United States, 591-592
  - skin color and, 591
- metastatic work-up in, 683-684
- pathology of, 659-676
  - ABCDs in, 671
  - clinicopathologic features, 659
  - desmoplastic and neurotropic melanomas, 673
  - histogenetic subtypes, 659-661
  - histologic reporting in, 673-674
  - in acral-mucosal regions, 669-670
  - in dermis, 671-672

- of acral-mucosal regions, 673
- of head and neck, 673
- of trunk and proximal extremities, 672-673
- in head and neck, 666-669
- in trunk and proximal extremities, 664-666
- mitotic rate, 674
- nodular melanoma, 672
- precursor lesions, 662
- satellite lesions, 674
- thickness, 674, 682-683
- tumor progression model, 663
- ulceration, 674
- vascular invasion, 674
- prevention of
  - sunblocks in, 601-602
  - sunscreens in. *See* Sunscreens.
- prognostic factors for, **647-658**
  - age, 651-652
  - anatomic site, 651
  - cell type, 652
  - gender, 651
  - growth patterns, 652
  - inflammatory response, 652
  - level of dermal invasion, 650-651
  - markers as, 653
  - mitotic rate, 652
  - regression, 652
  - staging, 649-650, 682-683
  - TNM system, 647-649
    - M classification, 649
    - N classification, 648-649
    - T classification, 647-648
  - vascular invasion, 652-653
- radiation therapy for, **713-716**
  - palliative, 713-714
  - potentially curable, 714-715
- risk factors for, **597-600**, 681-682
  - gender, 632
  - genetics, 597-599
  - place of birth, 599
  - previous melanoma, 599
  - socioeconomic status, 599, 632
- screening for, **629-640**
  - criteria for, 630-631
  - dermatologists in, 632-634
  - guidelines for, 631
  - in high-risk populations, 631-632
  - in primary care setting, 634
  - physician and nurse training in, 637
  - rationale for, 629-630
- surgery for, **681-699**
  - adjuvant immunotherapy with, 686-687
  - excisional margins in, 684, 701-702
  - follow-up of, 687
  - for clinically negative lymph nodes, 684-686
  - for clinically positive lymph nodes, 686
  - for facial melanoma, 691-692
  - for lesions of uncertain diagnosis, 692-693
  - for local recurrence, 687-688
  - for plantar melanoma, 691
  - for subungual melanoma, 690-691
  - in pregnancy, 693-694
  - Mohs' micrographic. *See* Mohs' micrographic surgery.
  - surveillance of, total body photography in, 623
  - unifying concept for, 660-661
  - unusual types of, **727-733**
    - amelanotic, 727-728
    - desmoplastic, 728-729
    - malignant blue nevi, 729-730
    - nevus of Ota-associated, 730-731
    - subungual, 731
  - vaccines for. *See* Vaccines.
- Melasma, laser therapy for, 42
  - complications of, 172
- Melanin, as marker, for melanoma, 653
- Meningitis, aseptic, clinical features of, 219
- Menkes disease, cutaneous features of, 555
- Mental nerve blocks, in laser therapy, 130
- Mentalis folds, botulinum toxin for, 756
- Menzies method, to diagnose melanoma, 644
- Metabolic disorders, and pruritus, 465-466
- Metastatic calcifications, in dialysis patients, 517-518
- Metastatic disease, cutaneous, from thyroid malignancies, 474
- Microdermabrasion, with laser therapy, for striae distensae, 74-75
- Micrometastases, from melanoma, 69, 648
- Microphthalmia transcription factor, as marker for desmoplastic melanoma, 729
- Microwave delivery system, in hair removal, 142
- Milker's nodules, cutaneous features of, 345
- Mitotic rate, in melanoma, 652, 674
- Mixed cryoglobulinemia, hepatitis C and, 239-240
- Mohs' micrographic surgery
  - for lentigo maligna, 705
  - for melanoma, **701-708**

- excisional margins in, 704
  - histologic stains in, 704-705
  - historical aspects of, 703
  - of ears, 706
  - of feet, 706
  - of nails, 705-706
  - of nose, 706
  - of oral cavity, 706
  - paraffin sections in, 705
  - periorbital, 706
- Mole monitoring, in melanoma, 737
- Molecular markers, for melanoma, 653
- Molluscum contagiosum
- cutaneous features of, 343-344
  - with HIV infection, 196-197
- Monkeypox, cutaneous features of, 345
- Monoclonal gammopathy, and scleredema, 493-494
- Mononucleosis, infectious, Epstein-Barr virus infection and, 283-285
- Mouth frowns, botulinum toxin for, 756
- Mucinoses, diffuse cutaneous. *See* Diffuse cutaneous mucinoses.
- Muir-Torre syndrome, with gastrointestinal disease, 542
- Multicentric Castleman's disease, human herpesvirus 8 and, 310-311
- Multiple endocrine neoplasia
- and pruritus, 466
  - cutaneous metastases from, 474
  - with gastrointestinal disease, 542
  - with thyroid disease, 478
- Multiple sclerosis, and pruritus, 466
- Muscle abnormalities, in dermatomyositis, 394-395
- Musculoskeletal features, of sarcoidosis, 438
- Mycobacteria
- and sarcoidosis, 440
  - with HIV infection, 197-198
- Mycosis fungoides, pruritus with, 465
- Myobloc. *See* Botulinum toxin.
- Myocarditis, enterovirus infections and, 219-220
- Myopathies, idiopathic inflammatory.
- See* Dermatomyositis.
- Myxedema, with hypothyroidism, 477, 498-499
- Myxoma, with cardiac disease, 509
- N**
- Nail-patella syndrome, cutaneous and renal features of, 514
- Nalmefene, for pruritus, 464
- Naloxone, for pruritus, 464
- Naltrexone, for pruritus, 462, 464, 468
- Nasal melanoma, Mohs' micrographic surgery for, 706
- Nasolabial folds, botulinum toxin for, 756
- Nausea and vomiting, regional anesthesia and, 132
- Naxos disease, with cardiac disease, 509
- Nd:YAG lasers
- for hemangiomas, 8
  - for leg telangiectasias, 22
  - for pigmented lesions, complications of, 172
  - in hair removal, 137, 141, 566-567
  - in skin resurfacing, 99-100, 102-103, 105-106
  - complications of, 169
  - in tattoo removal, 49
- Necrobiosis lipoidica, in diabetes mellitus, 483-484
- Necrolytic migratory erythema, cutaneous features of, 523-524
- Necrotizing angitis, with gastrointestinal disease, 544
- Neonatal panniculitis, cutaneous features of, 429
- Nephrology, cutaneous. *See* Cutaneous nephrology.
- Nerve blocks, facial. *See* Facial blocks.
- Neuralgia, postherpetic, clinical features of, 272
- Neurocutaneous disorders, **547-560**
- ataxia-telangiectasia, 553-554
  - basal cell nevus syndrome, 550-551
  - epidermal nevus syndrome, 551-552
  - incontinentia pigmenti, 554-555
  - Menkes disease, 555
  - neurofibromatosis, 547-549
  - POEMS syndrome, 555-556
  - tuberous sclerosis, 549-550
  - xeroderma pigmentosum, 552-553
- Neurofibromatosis, cutaneous and renal features of, 513, 547-549
- Neurologic complications
- of herpes zoster virus, 272
  - of measles, 211
  - of sarcoidosis, 438



- of varicella, 269
  - of xeroderma pigmentosum, 553
  - Neurologic disorders, and pruritus, 466
  - Neurologic examinations, for congenital melanocytic nevi, 614
  - Neuropeptides, in pruritus, 460
  - Neurotropic melanoma, pathology of, 673
  - Neutrophilic dermatoses, **409-419**
    - bowel associated dermatosis-arthritis syndrome, 416-417
    - neutrophilic eccrine hidradenitis, 417
    - pyoderma gangrenosum, **347-355**, 412-416
      - atypical or bullous, 413-414
      - cutaneous features of, 412
      - diagnosis of, 347-349, 414-415
      - differential diagnosis of, 415
      - diseases associated with, 414
      - etiology and pathogenesis of, 414
      - histopathology of, 414
      - malignant, 413
      - management of, 351-354, 415-416
        - systemic, 352-353
        - topical and intralesional, 351-352
      - peristomal, 412-413
      - stabilizing patient with, 350
      - systemic disease with, 349-350
      - vulvar, 413
      - with hepatitis C, 453
      - with inflammatory bowel disease, 533-536
      - wound care in, 350-351
    - rheumatoid, 416
  - Sweet's syndrome, 409-412, 528
    - diagnosis of, 411
    - diseases associated with, 410-411
    - epidemiology of, 409
    - histopathology of, 409-410
    - laboratory findings in, 409
    - management of, 411-412
    - pathogenesis of, 411
    - with gastrointestinal disease, 536-537
    - with thyroid disease, 478-479
  - Nevi
    - dysplastic. *See* Dysplastic nevi.
    - laser therapy for
      - complications of, 172
      - congenital, 43-44
      - epidermal, 155
      - nevocellular, 42-43
      - sebaceous, 157
    - melanocytic. *See* Congenital melanocytic nevi.
    - Nevi spilus, laser therapy for, 42
  - Nevirapine, adverse reactions to, in HIV infection, 203
  - Nevus of Ito, laser therapy for, 44-45
  - Nevus of Ota
    - and melanoma, 730-731
    - laser therapy for, 44-45
  - New Zealand, melanoma in, 589, 591
  - Nicotine patches, for pyoderma gangrenosum, 352
  - Nitrosoureas, for melanoma, 709
  - Nodular vasculitis, panniculitis with, 431
  - Nonablative lasers
    - for striae distensae, 68-69
    - in skin resurfacing. *See* Skin resurfacing.
  - Nonlaser light sources, in hair removal, 566
  - Nonmelanoma skin cancers, curettage and electrodesiccation for. *See* Curettage and electrodesiccation.
  - Nonnucleoside reverse transcriptase inhibitors, adverse reactions to, in HIV infection, 203
  - Nonpolio enterovirus infections
    - clinical features of, 219
    - epidemiology of, 218
  - Noonan's syndrome, with cardiac disease, 508
  - Nucleoside analogues, for hepatitis B, 237
  - Nucleoside reverse transcriptase inhibitors, adverse reactions to, in HIV infection, 203
- 
- O**
- Oasis grafts, for chronic wounds, 358-359
  - Occlusive dressings, for chronic wounds, 357
  - Ocular abnormalities
    - in ataxia-telangiectasia, 553
    - in herpes zoster virus, 273
    - in sarcoidosis, 437
    - in xeroderma pigmentosum, 553
  - Odontogenic keratocysts, in basal cell nevus syndrome, 551
  - Ondansetron, for pruritus, 462, 468
  - Opioid antagonists, for pruritus, 464, 468
  - Opioids, in pruritus, 460
  - Oral hairy leukoplakia
    - Epstein-Barr virus infection and, 285-286
    - with HIV infection, 195

- Oral melanoma, Mohs' micrographic surgery for, 706
- Orf, cutaneous features of, 345
- Osler-Weber-Rendu disease, with gastrointestinal disease, 544
- Osteo-onychodysplasia, cutaneous and renal features of, 514

## P

- PABA, in sunscreens, to prevent melanoma, 602, 604
- Paclitaxel, for melanoma, 709
- Palmar pits, in basal cell nevus syndrome, 550-551
- Pancreatic disease, panniculitis with, 429, 539
- Panencephalitis, subacute sclerosing, measles and, 211
- Panniculitis, 421-433
- cutaneous polyarteritis nodosa, 424-425
  - cytaphagic histiocytic, 425, 428
  - eosinophilia myalgia syndrome, 423-424
  - eosinophilic fasciitis, 422-423
  - erythema nodosum, 421-422
  - idiopathic lobular, 425
  - infectious, 430-431
  - lipodermatosclerosis, 422
  - neonatal, 429
  - physical, 428-429
  - polyarteritis nodosa, 424
  - post-steroid, 429
  - scleroderma panniculitis, 422
  - superficial migratory thrombophlebitis, 424
  - with  $\alpha_1$ -antitrypsin deficiency, 431
  - with calciphylaxis, 430
  - with leukemia and lymphoma, 430
  - with lupus erythematosus, 430
  - with nodular vasculitis, 431
  - with pancreatic disease, 429, 539
  - with subcutaneous sarcoidosis, 430, 436
- Papanicolaou smear, in prevention, of human papillomavirus, 324
- Papillomavirus. *See* Human papillomavirus.
- Papular acrodermatitis of childhood, hepatitis B and, 235-236
- Papular purpuric "gloves and socks" syndrome, parvovirus B19 infection and, 335-336
- Paraffin sections, in Mohs' micrographic surgery, for melanoma, 705
- Paraneoplastic dermatoses, 523-532
- acanthosis nigricans, 525
  - acquired ichthyosis, 525-526
  - Bazex's syndrome, 526
  - carcinoid syndrome, 524
  - clubbing, 530
  - coagulopathy, 529
  - Cronkhite-Canada syndrome, 530
  - cryoglobulinemia, 530
  - Cushing's syndrome, 524
  - cutaneous amyloidosis, 528-529
  - dermatomyositis. *See* Dermatomyositis.
  - erythema gyratum repens, 526
  - erythroderma, 529
  - hypertrichosis lanuginosa acquisita, 525
  - multicentric reticulohistiocytosis, 528
  - necrolytic migratory erythema, 523-524
  - paraneoplastic pemphigus, 526-527
  - sign of Leser-Trélat, 524-525
  - Sweet's syndrome. *See* Neutrophilic dermatoses.
  - tripe palms, 525
- Paraproteinemia, with pyoderma gangrenosum, 414
- Parathyroidectomy, subtotal, for pruritus, 462
- Paravaccinia, cutaneous features of, 345
- Paroxetine, for pruritus, 468
- Parvovirus B19 infection, 333-342
- clinical features of, 334
  - cutaneous features of, 3334-336
  - diagnosis of, 337
  - epidemiology of, 333
  - histopathology of, 336
  - in pregnancy, 337-338
  - management of, 340
  - pathogenesis of, 337
  - populations at risk for, 337
  - rheumatologic complications of, 339
  - transmission of, 333
  - vascular complications of, 338-339
- Peginterferon alpha-2b, for mixed cryoglobulinemia, 240
- Pemphigus, paraneoplastic, cutaneous features of, 526-527
- Penciclovir, for herpes simplex virus, 257, 259
- Periocular crow's feet, botulinum toxin for, 755-756
- Perioral rhytides, botulinum toxin for, 756
- Perioral skin, photodamaged, laser therapy for, 93
- Periorbital melanoma, Mohs' micrographic surgery for, 706
- Peripheral nervous system, in scleromyxedema, 496

- Peripheral vascular disease, in cardiac disease, 504-505
- Peristomal pyoderma gangrenosum, cutaneous features of, 412-413
- Peutz-Jeghers syndrome, with gastrointestinal disease, 542
- Photochemotherapy, for pruritus, 462, 464, 467-468
- Photodamaged skin, laser therapy for. *See* Skin resurfacing.
- PhotoDerm VL  
for leg telangiectasias, 14, 31-33  
parameters for, 5
- Photodynamic therapy, in hair removal, 138
- Photosensitivity disorders, with HIV infection, 203-204
- Physical panniculitis, cutaneous features of, 428-429
- Pigmented lesions, laser therapy for, 37-45  
argon lasers in, 37  
Becker's nevus, 42  
blue nevi, 45  
café-au-lait macules, 41-42, 171-172  
complications of, 171-172  
compound melanocytic nevi, 43  
congenital nevi, 43-44, 172  
continuous-wave lasers in, 38  
ephelides, 41  
junctional melanocytic nevi, 43  
lentigo simplex and solar lentigo, 40  
long-pulsed lasers in, 39  
melasma, 42, 172  
nevocellular nevi, 42-43  
nevus of Ota and nevus of Ito, 44-45, 172  
nevus spilus, 42  
postinflammatory hyperpigmentation, 42  
preoperative preparation for, 39  
pulsed dye lasers in, 39  
Q-switched lasers in, 38-40, 42-43, 171-172  
ruby lasers in, 37  
seborrheic keratoses and dermatosis papulosa nigra, 40-41, 155
- Pigmented pretibial papules, in diabetes mellitus, 484
- Pigmented scars, revision of, lasers in, 57, 62-63
- Piokiloderma of Civatte, laser therapy for, 12
- Pityriasis rosea, human herpesvirus 7 and, 304-305
- Planar xanthomas, in cardiac disease, 504
- Plantar melanoma, surgery for, 691  
Mohs' micrographic, 706
- Plantar pits, in basal cell nevus syndrome, 550-551
- Plasmapheresis, for pruritus, 463
- Platelet-derived growth factor, for chronic wounds, 358
- Platysmal rejuvenation, botulinum toxin for, 756-757
- Pleconaril, for enterovirus infections, 221
- Plummer-Vinson syndrome, with gastrointestinal disease, 542-543
- Pneumonia, measles and, 211
- Pneumonitis, interstitial, with dermatomyositis, 396-397
- POCKit HSV-2 Rapid Test, for herpes simplex virus, 255
- Podophyllin, for human papillomavirus, 320-321
- Podophyllotoxin, for human papillomavirus, 320-321
- POEMS syndrome, cutaneous features of, 555-556
- Poliovirus infections. *See* Enterovirus infections.
- Polyarteritis nodosa  
cutaneous and renal features of, 424-425, 515  
hepatitis B and, 235  
with hepatitis C, 453
- Polymerase chain reaction, for hepatitis C, 454
- Polymerase chain reaction technique  
for cytomegalovirus infections, 294-295  
for enterovirus infections, 220  
for herpes simplex virus, 255  
for measles, 211
- Polymyositis. *See* Dermatomyositis.
- Porcine xenografts, for chronic wounds, 358-359
- Porphyria cutanea tarda  
hepatitis C and, 240-241  
in dialysis patients, 517  
with gastrointestinal disease, 539  
with hepatitis C, 451-452  
with HIV infection, 203-204
- Port-wine stains, laser therapy for, 8-10  
complications of, 172-173
- Post-steroid panniculitis, cutaneous features of, 429
- Potassium titanyl phosphate lasers. *See* KTP lasers.
- Poxvirus infections, 343-346  
genus Molluscipoxvirus in, 343-344  
molluscum contagiosum, 343-344

- genus Orthopoxvirus in, 344-345
  - cowpox, 345
  - monkeypox, 345
  - vaccinia, 344-345
  - variola, 344
- genus Parapoxvirus in, 345
  - orf, 345
  - pseudocowpox, 345
- genus Yatapoxvirus in, 345-346
  - tanapox, 345
- PP65 antigenemia assay, for cytomegalovirus infections, 294
- Pregnancy
  - herpes simplex virus in
    - diagnosis of, 255
    - management of, 258-259
    - recurrent, 253
  - herpes zoster virus in, 271
  - melanoma in, 693-694
  - parvovirus B19 infection in, 337-338
  - varicella in, 269
- Primary effusion lymphomas, human herpesvirus 8 and, 311
- Procuren, for chronic wounds, 357-358
- Proliferative markers, for melanoma, 653
- Propofol
  - for pruritus, 464
  - intraoperative, in laser therapy, 128
- Prostaglandins, in pruritus, 460
- Protease inhibitors, adverse reactions to, in HIV infection, 203
- Pruritus, 459-472
  - cholestasis and, 462-464
  - hematopoietic disease and, 464-465
  - hepatitis C and, 452-453
  - in dialysis patients, 516-517
  - malignancies and, 466
  - management of, 462-465, 467-468
  - mediators of itching in, 459-460
  - metabolic and endocrine disorders and, 465-466
  - neurologic disorders and, 466
  - pathophysiology of, 459-460
  - patient evaluation for, 460-461
  - renal disease and, 461-462
- PS-341, for melanoma, 711
- Pseudocowpox, cutaneous features of, 345
- Pseudohypopigmentation, laser skin resurfacing and, 94
- Pseudoxanthoma elasticum
  - cutaneous and renal features of, 514
  - with cardiac disease, 508
  - with gastrointestinal disease, 545
- Psoriasis, with HIV infection, 202
- Psychodermatology, nonpharmacologic managements in, 177-185
  - biofeedback, 178
  - case reports of, 179-183
    - acne and excoriated acne, 181
    - adult eczema, 181
    - eczema, 180-181
    - pruritus, 182-183
    - psoriasis, 179-180
    - urticaria, 182
  - hypnosis, 178-179
  - psychoeducation and support, 179
  - psychotherapy, 179
  - relaxation training, 178
- Psychoeducation, in psychodermatology, 179
- Psychotherapy, in psychodermatology, 179
- Pulmonary disease, with dermatomyositis, 395-397
- Pulmonary features, of sarcoidosis, 437
- Pulsed carbon dioxide lasers, in tattoo removal, 49-50
- Pulsed dye lasers
  - for epidermal and dermal lesions, 151-152
  - for facial telangiectasias, 10
  - for hemangiomas, 6-7
  - for leg telangiectasias, 14, 24, 26
  - for pigmented lesions, 39
  - for poikiloderma of Civatte, 12
  - for port-wine stains, 8-10
  - for pyogenic granulomas, 13
  - for rosacea-associated telangiectasias and erythema, 12
  - for spider angiomas, 12
  - for striae distensae, 69
  - for vascular lesions
    - complications of, 172-173
    - for venous lakes, 13
  - in scar revision, 59-60
  - in skin resurfacing, 98-99
- Pulsed erbium lasers, in tattoo removal, 49-50
- Purpura, parvovirus B19 infection and, 334
- Pustular pyoderma gangrenosum, diagnosis of, 347-348
- Pustular reactions, in gastrointestinal disease, 538

- Pustulosis palmoplantar, with thyroid disease, 478
- Pyoderma gangrenosum. *See*  
Neutrophilic dermatoses.
- Pyogenic granulomas, laser therapy for, 12-13
- Pyostomatitis vegetans, cutaneous features of, 413

## Q

- Q-switched lasers
- for pigmented lesions, 38-40, 42-43
  - complications of, 171-172
  - in hair removal, 137, 141
  - in skin resurfacing, 99-100
  - in tattoo removal, 48-49, 158
  - complications of, 169-171
- Quinacrine
- for cutaneous lupus erythematosus, 379
  - for dermatomyositis, 400

## R

- Radiation therapy, for melanoma, **713-716**
- palliative, 713-714
  - potentially curable, 714-715
- Radiofrequency devices, in laser skin resurfacing, 109
- Ray amputation, for subungual melanoma, 690
- Recurrent necrotic papulovesicles of face, Epstein-Barr virus infection and, 287
- Regional anesthesia, in laser therapy, **123-134**
- and respiratory depression, 132
  - complications of, 132-133
  - discharge criteria for, 133
  - facial blocks in, 128-130
  - complications of, 130
  - inadequate, 132
  - intraoperative intravenous sedation in, 128
  - intraoperative patient comfort in, 130-131
  - patient selection for, 124-126
  - premedication for, 127-128
  - preoperative evaluation for, 126
  - standards for, 123-124
  - technique for, 126-127
- Regrenex, for chronic wounds, 358
- Reiter's syndrome, with HIV infection, 202
- Relapsing polychondritis, with cardiac disease, 505-506
- Relaxation training, in psychodermatology, 178
- Renal disease, and pruritus, 461-462
- Renal lesions, in tuberous sclerosis, 550
- Renal transplant patients, cutaneous and renal findings in, 518-519
- Repifermin, for chronic wounds, 358
- Resiquimod, for herpes simplex virus, 258
- Respiratory complications
- of regional anesthesia, 132
  - of varicella, 269
- Reticular erythematous mucinosis, cutaneous, 497-498
- Reticulohistiocytosis, multicentric, cutaneous features of, 528
- Retinoic acid, in skin preparation, for laser resurfacing, 116
- Retinoids, for cutaneous lupus erythematosus, 380
- Rheumatoid neutrophilic dermatitis, cutaneous features of, 416
- Rheumatologic complications, of parvovirus B19 infection, 339
- Rhinophyma, laser therapy for, 155-157
- Ribavirin
- for hepatitis C, 455
  - for measles, 214
  - for mixed cryoglobulinemia, 240
- Rifampin, for pruritus, 463
- Rosacea
- erythema with, laser therapy for, 12
  - telangiectasias with, laser therapy for, 12
- Roseola infantum, human herpesvirus 6 and, 303
- RT-PCR, for melanocytic proteins, 653
- Rubella, **225-231**
- clinical features of, 226
  - congenital rubella syndrome, 227-230
  - clinical features of, 227-228
  - cutaneous features of, 228
  - diagnosis of, 228-229
  - differential diagnosis of, 228
  - management of, 229
  - mechanisms of teratogenesis in, 227
  - pathology of, 229
  - prevention of, 229
  - differential diagnosis of, 227
  - epidemiology of, 225-226
  - incidence of, 225

- laboratory findings in, 226
  - management of, 227
  - pathology of, 226
  - recent outbreaks of, 229-230
  - viral structure of, 225
- Rubeosis faciei, in diabetes mellitus, 487
- Ruby lasers
- for pigmented lesions, 39
  - in hair removal, 139-140, 562-563
  - in tattoo removal, 48-49
- RubyStar lasers, in hair removal, 139
- S**
- 
- S-100, in Mohs' micrographic surgery, for melanoma, 704
- Salicylates, in sunscreens, to prevent melanoma, 602-603
- Sarcoidosis, 435-447
- bone marrow involvement in, 437-438
  - cardiac features of, 428
  - cutaneous features of, 435-437
  - diagnosis of, 440-441
  - disease progression in, 441
  - diseases associated with, 440
  - endocrine features of, 428
  - etiology of, 439-440
    - genetics in, 439-440
    - immunology in, 439
    - infectious and environmental factors in, 440
  - hepatic features of, 428
  - histopathology of, 440
  - in children, 439
  - incidence and epidemiology of, 439
  - lymphadenopathy in, 437
  - management of, 441-442
  - musculoskeletal features of, 428
  - neurologic features of, 428
  - ocular features of, 437
  - prognosis for, 442
  - pulmonary features of, 437
  - splenomegaly in, 437
  - subcutaneous, panniculitis with, 430
- Scabies, with HIV infection, 201
- Scars
- avoidance of, in laser skin resurfacing, 118-119, 168-169
  - revision of
    - acne scars, 83-84
    - atrophic scars, 57, 60-62
    - hypertrophic scars, 56, 59-60
    - keloids, 56-57, 59-60
    - lasers in, 55-65
    - pigmented scars, 57, 62-63
    - preoperative evaluation for, 57-59
    - striae distensae. *See* Striae distensae.
- Scleredema, cutaneous features of, 493-495
- Scleroderma, with cardiac disease, 505
- Scleroderma panniculitis, cutaneous features of, 422
- Scleromyxedema
- cutaneous, 495-497
  - with hyperthyroidism, 475
- Sebaceous nevi, laser therapy for, 157
- Seborrheic dermatitis, with HIV infection, 202
- Seborrheic keratoses, laser therapy for, 40-41, 155
- Sentinel lymphadenectomy, in melanoma, 684-686
- Serotonin, in pruritus, 459-460
- Serotonin antagonists, for pruritus, 468
- Serum sickness-like syndrome, hepatitis B and, 236
- Serum tumor markers, for internal malignancies, in dermatomyositis, 399
- Sexual activity
- and hepatitis B, 234
  - and hepatitis C, 238, 449-450
  - and herpesvirus 8, 310
- Sexually transmitted diseases, prevention of, education in, 323
- Shin spots, in diabetes mellitus, 484
- Shulman's syndrome, cutaneous features of, 422-423
- Sign of Leser-Trélat, in paraneoplastic dermatoses, 524-525
- Sjögren's syndrome, with hepatitis C, 452
- Skin, photodamaged, laser therapy for. *See* Skin resurfacing.
- Skin cancer, laser therapy for, 155
- Skin resurfacing
- botulinum toxin with, 757
  - carbon dioxide lasers in, 77-86
    - collagen tightening in, 78-80
    - complications of, 166, 168-169
    - for acne scars, 83-84
    - for advanced damage, 82-83
    - for early damage, 81-82
    - for moderate damage, 82

- indications for, 80-81
  - physics of, 77-78
  - Er:YAG lasers in, **87-96**, 108-109
    - complications of, 93-94, 166, 168-169
    - laser-tissue interaction in, 87-89
    - patient selection for, 89-90
    - results of, 90-93
    - with carbon dioxide laser therapy, 93
  - for age-related changes, 97-98
  - in darkly pigmented persons, lasers in, **113-121**
    - intraoperative period in, 117
    - postoperative care for, 117-119
    - predictable technique for, 119
    - preoperative preparation for, 114, 116-117
    - wound care in, 119-120
  - nonablative lasers in, **97-112**
    - diode lasers, 100, 106-108
    - erbium glass lasers, 104-105
    - intense pulsed light source, 101-102
    - Nd:YAG lasers, 105-106
    - pulsed dye lasers, 98-99
    - Q-switched Nd:YAG lasers, 99-100
    - radiofrequency device in, 109
    - short- and long-wavelength lasers, 102-103
  - Skin self-examination, for melanoma, 635-636
  - Skin tumors, malignant, human papillomavirus and, 318
  - "Slapped cheek" appearance, parvovirus B19 infection and, 334-335
  - Small-cell melanoma, of trunk and proximal extremities, 672-673
  - Smallpox, cutaneous features of, 344
  - Softlight System, in hair removal, 137-138
  - Solar lentigo, laser therapy for, 40
  - SPF system, in sunscreens, to prevent melanoma, 603
  - Spider angiomas, laser therapy for, 12
  - Spindle-shaped cell melanoma, of trunk and proximal extremities, 672
  - Staphylococcal infections, with HIV infection, 197
  - Steroids
    - for cutaneous lupus erythematosus, 378-379
    - for dermatomyositis, 400-401
    - for herpes zoster virus, 275-276
    - for infectious mononucleosis, 285
    - for pyoderma gangrenosum, 351-352, 415-416
    - for sarcoidosis, 442
  - Striae distensae
    - origin of, 67
  - revision of, lasers in, 57, 60, **67-76**
    - ablative lasers, 74
    - historical aspects of, 68
    - infrared lasers, 69
    - microdermabrasion with, 74-75
    - pulsed dye lasers, 69
    - topical management with, 74
  - Stroke, pruritus after, 466
  - Subacute sclerosing panencephalitis, measles and, 211
  - Subungual melanoma
    - diagnosis of, 731
    - surgery for, 690-691
    - Mohs' micrographic, 705-706
  - Sun-damaged skin, melanoma of, 666-669, 673
  - Sunburns, and congenital melanocytic nevi, 613-614
  - Sunscreens
    - for cutaneous lupus erythematosus, 378
    - to prevent melanoma, **601-606**, 623
      - benzophenones in, 602
      - cinnamates in, 602
      - clinical studies of, 605-606
      - dibenzoylmethanes in, 603
      - historical aspects of, 601
      - PABA in, 602
      - reactions to, 604
      - salicylates and anthranilates in, 602-603
      - SPF system in, 603
      - vehicles for, 603-604
      - with immunologic damage, 604
  - Supra-orbital nerve blocks, in laser therapy, 129
  - Sweet's syndrome. *See* Neutrophilic dermatoses.
  - Syphilis, with HIV infection, 198
  - Systemic lupus erythematosus
    - parvovirus B19 infection and, 339
    - with cardiac disease, 505
    - with hepatitis C, 453
  - Systemic sclerosis
    - cutaneous and renal features of, 515
    - parvovirus B19 infection and, 339
- 
- ## T
- Tacrolimus, for pyoderma gangrenosum, 353
  - Tanapox, cutaneous features of, 345
  - Tattoo removal, lasers in, 45-50, 158
    - anesthesia in, 50
    - complications of, 45, 48, 169-171

- pulsed carbon dioxide and erbium lasers in, 49-50
  - Q-switched alexandrite lasers in, 49
  - Q-switched Nd:YAG lasers in, 49
  - Q-switched ruby lasers in, 48-49
  - technique for, 50
  - wound care in, 50
- Taxanes, for melanoma, 709
- Telangiectasias
- facial, laser therapy for, 10-11
  - complications of, 173
  - gingival, in dermatomyositis, 394
  - hereditary hemorrhagic, with gastrointestinal disease, 544
  - leg. *See* Leg telangiectasias.
  - rosacea-associated, laser therapy for, 12
- Teledermatology, to diagnose melanoma, 736-737
- Temozolomide, for melanoma, 711
- Tendinous xanthomas, in cardiac disease, 504
- Thalidomide
- for cutaneous lupus erythematosus, 379
  - for pruritus, 462
- Thick skin, in diabetes mellitus, 486-487
- Thrombophlebitis, superficial migratory, cutaneous features of, 424
- Thyroglossal duct cysts, cutaneous features of, 473-474
- Thyroid disease, **473-481**
- adult hypothyroidism, 477
  - alopecia area with, 477
  - anemia with, 477
  - bullous disorders with, 477-478
  - congenital hypothyroidism, 476-477
  - connective tissue diseases with, 478
  - endocrinopathies with, 478
  - Graves' disease, 475-476
  - hyperthyroidism, 474-475
  - hypothyroidism, 476
  - McCune-Albright syndrome with, 479
  - pustulosis palmoplantaris with, 478
  - Sweet's syndrome with, 478-479
  - thyroglossal duct cysts, 473-474
  - urticaria with, 478
  - vittiligo with, 478
- TNM system, to classify melanoma, 647-649
- Total body photography, in melanoma surveillance, 622
- Transcutaneous electrical nerve stimulation, for pruritus, 468
- Traumatic tattoos, laser therapy for, 170
- Treponema pallidum*, with HIV infection, 198
- Tretinoin
- in skin preparation, for laser resurfacing, 116
  - with laser therapy, for striae distensae, 74
- Trichloroacetic acid, for human papillomavirus, 320
- Trichophyton rubrum*, with HIV infection, 199
- Trimethoprim-sulfamethoxazole, adverse reactions to, in HIV infection, 203
- Tripe palms, cutaneous features of, 525
- Trunk, melanoma of, 664-666, 672-673
- Tuberculosis, with HIV infection, 197-198
- Tuberous sclerosis, cutaneous and renal features of, 513-514, 549-550
- Tuberous xanthomas, in cardiac disease, 504
- Tumid cutaneous lupus erythematosus, diagnosis of, 377
- Tumor necrosis factor
- in cutaneous lupus erythematosus, 374
  - in dermatomyositis, 402
  - in limb perfusion, for recurrent melanoma, 688-689
- 
- U**
- Ulceration, to classify melanoma, 648
- Ulcerative colitis
- cutaneous features of, 533
  - with pyoderma gangrenosum, 414
- Ulcerative pyoderma gangrenosum, diagnosis of, 347
- Ulcers, genital, infectious mononucleosis and, 284-285
- Ultra-long pulsed dye lasers
- for facial telangiectasias, 10-11
  - for leg telangiectasias, 14
  - parameters for, 4-5
- Ultraviolet light
- avoidance of, for dermatomyositis, 400
  - sensitivity to, dysplastic nevi and, 619
- Urticaria
- with hepatitis C, 452
  - with thyroid disease, 478



## V

## Vaccines

- for congenital rubella syndrome, 229
- for hepatitis B, 237
- for herpes simplex virus, 260-261
- for human papillomavirus, 322-324
- for measles, 213-214
- for melanoma, **717-725**
  - adjuvant, 721
  - choice of, 724
  - clinical trials of, results of, 721-723
  - nonpurified, 719-720
  - partially purified, 720-721
  - patient information on, 723
  - patient selection for, 723
  - purified, 720
  - rationale for, 717
  - requirements for, 717-719
- for vaccinia, 344-345
- for varicella, 276-277

Vaccinia, cutaneous features of, 344-345

## Valacyclovir

- for herpes simplex virus, 256-258
- for herpes zoster virus, 275

Varicella-zoster virus infection, **267-282**

- herpes zoster virus in, 270-273
  - acute, 270-271
  - chronic, 271-272
  - clinical features of, 272
  - complications of, 272-273
  - in immunocompromised patients, 271
  - in pregnancy and neonatal period, 271
  - management of, 275-276
    - failure of, 276
  - pathogenesis of, 270
- varicella in, 267-270
  - clinical features of, 268-269
  - complications of, 269-270
  - diagnosis of, 273-275
  - in immunocompromised patients, 268-269
  - in pregnancy and neonatal period, 269
  - management of, 273-275
  - pathogenesis of, 267-268
  - prevention of, 276-277
    - postexposure, 277-278
  - with HIV infection, 194-195
- Varicella-zoster virus-specific immune globulin, for varicella-zoster virus infection, 277-278

Variola, cutaneous features of, 344

Vascular complications, of parvovirus B19 infection, 338-339

Vascular invasion, by melanoma, 652-653, 674

Vascular lesions, laser therapy for, **1-8**

- alexandrite lasers in, 5-6
- argon-pumped tunable dye lasers in, 2, 11
- cherry angiomas, 13-14
- complications of, 172-173
- continuous-wave argon lasers in, 1-2, 6-7, 10
- copper vapor and copper bromide lasers in, 2, 11-12
- diode lasers in, 3, 6
- facial telangiectasias, 10-11, 173
- hemangiomas, 6-8, 173
- intense pulsed light source in, 5, 14
- krypton lasers in, 2
- KTP lasers in, 2
- leg telangiectasias. *See* Leg telangiectasias.
- long-pulsed dye lasers in, 4, 14
- Nd:YAG lasers in, 8
- poikiloderma of Civatte, 12
- port-wine stains, 8-10, 172-173
- pulsed dye lasers in, 3-4, 6-10, 12-14
- pyogenic granulomas, 12-13
- rosacea-associated telangiectasias and erythema, 12
- spider angiomas, 12
- ultra-long pulsed dye lasers in, 4-5, 10-11, 14
- venous lakes, 13
- Versapulse lasers in, 6

VCAM-1, in dermatomyositis, 398

Vegetative pyoderma gangrenosum, diagnosis of, 348-349

Venous lakes, laser therapy for, 13

Vermillionectomy, lasers in, 154

Verrucae, laser therapy for, 150-152

Versapulse lasers, parameters for, 6

## Vertical transmission

- of hepatitis B, 234
- of hepatitis C, 238

Vinblastine, for melanoma, 709

Vinca alkaloids, for melanoma, 709

## Viral cultures

- of cytomegalovirus infections, 294
- of enterovirus infections, 220
- of herpes simplex virus, 254-255
- of herpes zoster virus, 273
- of pyoderma gangrenosum, 349

Viral hepatitis, **233-247**

- hepatitis A, 233

- hepatitis B, 233-237
  - and papular acrodermatitis of childhood, 235-236
  - and polyarteritis nodosa, 235
  - and serum sickness-like syndrome, 236
  - clinical features of, 234-235
  - epidemiology of, 234
  - management of, 237
  - prevention of, 236-237
  - risk factors for, 234
  - virology of, 233-234
- hepatitis C, 237-242
  - and lichen planus, 241-242
  - and mixed cryoglobulinemia, 239-240
  - and porphyria cutanea tarda, 240-241
  - clinical features of, 238-239
  - epidemiology of, 237
  - risk factors for, 237-238
  - virology of, 237
- Viral infections
  - and scleredema, 493
  - with HIV infection, 193-197
- Vitamin A, for measles, 214
- Vitiligo
  - with hepatitis C, 453
  - with thyroid disease, 478
- Vitrix, for chronic wounds, 362
- von Recklinghausen's disease, cutaneous and renal features of, 513
- Vulvar pyoderma gangrenosum, cutaneous features of, 413

---

**W**

- Weber-Christian disease, cutaneous features of, 425
- Wegener's granulomatosis, cutaneous and renal features of, 515-516
- Werner syndrome, with cardiac disease, 508-509
- Wound care, in pyoderma gangrenosum, 350-351
- Wounds, chronic. *See* Chronic wounds.

---

**X**

- Xanthomas, in cardiac disease, 504
- Xenografts, for chronic wounds, 358-359
- Xeroderma pigmentosum, cutaneous features of, 552-553
- Xerosis, with HIV infection, 201-202

---

**Y**

- Yellow skin, in diabetes mellitus, 487

---

**Z**

- Zidovudine, adverse reactions to, in HIV infection, 203
- Zoster sine herpete, clinical features of, 272

